

1-PL Welcome and Awards Plenary

Neuropathology in a multidisciplinary age

Eddie B Lee *has nothing to disclose* (University of Pennsylvania, PA, USA) - Neuropathology in a multidisciplinary age

1-26-PER-A Accelerating Therapeutic Development: A Global Commitment by the Alzheimer's Disease Sequencing Project (ADSP)

Mitigating Barriers to Participant Recruitment and Retention in the READD- ADSP Programme: Experience from the African Dementia Consortium.

Rufus O. Akinyemi, MBBS,MSc,PhD *has nothing to disclose*.

Back to the Future! Understanding old mechanisms and discovering new insights via ADSP initiatives

William S. Bush, PhD *has nothing to disclose*.

Increasing Amerindian diversity in AD genetics research, A Peruvian perspective

Mario Cornejo-Olivas, MD *has nothing to disclose*.

Identification of genetically driven Therapeutic Targets for Alzheimer's disease

Alison M. Goate, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Genentech - Consulting Fees

Muna Therapeutics - Consulting Fees

The Alzheimer's Disease Sequencing Project: Progress and Update

Margaret A Pericak-Vance, PhD *has nothing to disclose*.

Title: Reducing APOE4 in carriers is a therapeutic goal for Alzheimer Disease: Report of the APOE4 National Institute on Aging (NIA) /Alzheimer Disease Sequencing Project (ADSP) Consortium Working Group

Jeffery M. Vance, MD, PhD *has nothing to disclose*.

4-35-FRS-B Altered network functional connectivity, imbalance of excitatory and inhibitory influences, and underlying changes of synaptic density and endolysosomal system in the Frontotemporal Dementia spectrum

Pluripotent stem cell based and crispr engineered models of neurodegeneration to assess neuronal networks

Henrik Ahlenius, PhD *has nothing to disclose*.

Moving along the ALS-bvFTD spectrum: changes in MEG-based brain network topology

Rosanne Govaarts, PhD *has nothing to disclose.*

Functional connectivity associations with markers of disease progression in *GRN* mutation carriers

Suzee E. Lee, MD *has nothing to disclose.*

Interrogating the cognitive-behavioural impairment in a motor-dominant neurodegeneration (ALS), based on brain state dynamics of resting-state EEG

Marjorie Metzger, PhD *has nothing to disclose.*

The neurophysiological effects of frontotemporal lobar degeneration: linking synaptic loss, network connectivity and cognitive decline.

James B Rowe, PhD, FRCP *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Asceneuron - Consulting Fees

Astex - Consulting Fees

Astronautx - Consulting Fees

CumulusNeuro - Consulting Fees

Curasen - Consulting Fees

4-13-PER-B ARIA - Bench to Bedside and Back: Translating Cellular Mechanisms into Understanding Clinical Manifestations

CAA and ARIA: Emerging Concepts and Opportunities for Translation

Steven M. Greenberg, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Washington University/IQVIA - Consulting Fees

Neurovascular dysfunction, ApoE and innate immunity: co-conspirators in ARIA

Costantino Iadecola, MD *has nothing to disclose.*

Spontaneous and iatrogenic ARIA: mechanistic insights from CAA-related inflammation

Fabrizio Piazza, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Prothena - Consulting Fees

Roche - Consulting Fees

Introduction to what we still need to learn about ARIA

Reisa A Sperling, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consulting Fees

Acumen - Consulting Fees

Alector - Consulting Fees

Bristol-Myers-Squibb - Consulting Fees

Eisai - Contracted Research

Eli Lilly - Contracted Research

Genentech - Consulting Fees

Ionis - Consulting Fees

Janssen - Consulting Fees

Cerveau - Contracted Research

Janssen - Consulting Fees

Merck - Consulting Fees

Novartis - Consulting Fees

Understanding the cellular responses to anti-Abeta antibodies to gain insights into mechanisms of ARIA

Donna M. Wilcock, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association -

Biohaven - Consulting Fees

1-11-FRS-B Emerging neurobiology and clinical biomarker relevance of pT217-tau in Alzheimer's disease

P-tau217 significance as marker of brain Abeta and tau pathologies

Nicolas R. Barthélemy, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

C2N Diagnostics - Receipt of Intellectual Property Rights/Patent Holder

Localization, induction, and functional effects of tau phosphorylated at threonine 217

George S Bloom, PhD *has nothing to disclose.*

Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration

Dibyadeep Datta, PhD *has nothing to disclose.*

Neuropathologic investigation of phospho-threonine 217 provides neurobiologic insights into the intersection between amyloid- β and tau

Melissa E. Murray, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AVID Radiopharmaceuticals - Consulting Fees

Eli Lilly and Company - Contracted Research

Rainwater Charitable Foundation - Contracted Research

Plasma A β 42/A β 40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

Robert A Rissman, PhD *has nothing to disclose.*

3-15-FRS-C Mechanisms underlying brain resilience or pathogenesis in AD

Midlife modifiable AD risk presentation in women across the menopause transition

Jessica ZK Caldwell, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AARP - Consulting Fees

Physiological β -amyloid clearance by the liver and its therapeutic potential for Alzheimer's disease

Yuan Cheng, PhD *has nothing to disclose.*

Physical exercise upregulates Irisin in extracellular vesicles

Fernanda Guarino De Felice *has nothing to disclose.*

Integrative approach to profile resilience and risk factors in Alzheimer's disease

Ozkan Is, PhD *has nothing to disclose.*

Incorporating multi-omics in brain tissues to elucidate metabolic pathways linking diets to dementia

Jun Li, MD, PhD *has nothing to disclose.*

Maintaining brain resilience by normalizing NAD⁺/NADH prevents and reverses Alzheimer's disease

Andrew A. Pieper, PhD, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alchemab - Consulting Fees

4-25-FRS-C Sex differences in neurodegeneration and AD pathology

Evolutionary Theory and Machine Learning: New Inroads Into Sex-specific AD Susceptibility Genes and Pathways Significantly Improve Risk Prediction

Olivier Lichtarge, MD, PhD *has nothing to disclose.*

Genes that escape X chromosome inactivation are associated with Alzheimer's disease endophenotypes: findings from ROSMAP

Mabel Seto, PhD *has nothing to disclose.*

Translational profiling identifies sex-specific metabolic and epigenetic reprogramming of microglia in cerebral amyloidosis models with an antibiotic-altered gut microbiome

Shabana M Shaik, PhD *has nothing to disclose.*

Sex-specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in neurodegeneration

Yun Ju Sung, PhD *has nothing to disclose.*

Synergism between Lewy body and Alzheimer's disease pathology differs by sex

Madeline Wood Alexander *has nothing to disclose.*

Cell-type specific contribution to sex differences in Alzheimer's Disease revealed using single-cell transcriptomes

Yiyang Wu, MD, PhD *has nothing to disclose.*

2-32-FRS-C The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) at 10: Progress toward a precision medicine approach for AD

Integrating multi-omics data for target and biomarker discovery

Matthias Arnold, PhD *has nothing to disclose.*

Multi-omic approaches to defining disease heterogeneity, subtypes, and progression

David A. Bennett, MD *has nothing to disclose.*

Cellular dynamics across aged human brains uncover a multicellular cascade leading to Alzheimer's disease

Philip L. De Jager, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees, Contracted Research

Moderna - Consulting Fees

Lessons from Ten Years of Validation of Targets Identified by the Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD)

Michelle E. Ehrlich, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Aaronson, Rapoport -

Chiavetti, Corgan -

Heidell, Piitoni -

RPGKR -

Wilson Elser -

Altpep - Consulting Fees, Ownership Interest

Cognito - Consulting Fees

Eisai - Consulting Fees

GLG Group - Consulting Fees

Guidepoint - Consulting Fees

MEDACORP - Consulting Fees

SVB Securities - Consulting Fees

Third Bridge - Consulting Fees

Vigil - Consulting Fees

Ten year anniversary of AMP AD: Enabling a Precision Medicine Approach to Target and Biomarker Discovery for Alzheimer's Disease

Nilufer Ertekin-Taner, MD, PhD *has nothing to disclose.*

Peripheral Signatures of Disease Heterogeneity

Lenora A Higginbotham, MD *has nothing to disclose.*

4-12-FRS-C Understanding blood-brain barrier and neurovascular alterations in VCID and CAA: cellular, molecular mechanisms and therapeutic targets

Altered neutrophil glycolysis contributes to microvascular inflammation in an AD mouse model.

Oliver Bracko *has nothing to disclose.*

Uncovering the role of cerebrovascular phenotypes in AD through deep multi-omic molecular profiling of human brains

Ricardo D'Oliveira Albanus, PhD *has nothing to disclose.*

Brain Barrier Aging is Associated with Changes in Brain Plasticity and Decline in Processing Speed: A Proteomic Study of Human Cerebrospinal Fluid

Fanny M Elahi, MD *has nothing to disclose.*

Amyloid β and hyperhomocysteinemia promote endothelial cell apoptotic and mitochondrial stress, blood-brain barrier dysfunction and angiogenesis impairment.

Silvia Fossati, PhD *has nothing to disclose.*

Amyloid, iron and cerebrovasculopathy in a new mouse model combining hemochromatosis mutations and Alzheimer's amyloidosis and the etiological and diagnostic implications for dementia subtypes

Adrienne (Lz) Milward, PhD *has nothing to disclose.*

Blood-Brain Barrier Dynamics in Vascular Dementia: Unravelling the Tripartite Crosstalk between the Endothelium, Pericytes, and Microglia

Axel Montagne, PhD *has nothing to disclose.*

2-28-FRS-A Advancing plasma Alzheimer's Disease biomarkers: implementation in real-world settings and application for disease staging.

Alzheimer's disease blood tests of amyloid-beta 42/40, %p-tau217, 181, and 205 ratios and MTBR-243 in real-world populations: Results from SEABIRD and BioFINDER2

Randall J. Bateman, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

C2N Diagnostics - Receipt of Intellectual Property Rights/Patent Holder

Evaluation of the prospective use of blood biomarkers for Alzheimer's disease in primary and secondary care.

Oskar Hansson *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees

Eisai - Consulting Fees

Eli Lilly - Consulting Fees

Roche - Consulting Fees

Multi-analyte measurement of blood biomarkers for Alzheimer's disease: enabling concurrent analysis of affected pathophysiological processes

Thomas K Karikari, PhD *has nothing to disclose.*

Plasma Tau Biomarkers for Alzheimer's Disease Staging.

Laia Montoliu-Gaya, PhD *has nothing to disclose.*

2-19-PER-C Biomarker and diagnostic approaches to LATE

In vivo FDG-PET signatures of LATE

Michel J. Grothe, PhD *has nothing to disclose.*

MRI biomarkers to measure LATE in vivo

Renaud La Joie, PhD *has nothing to disclose.*

Clinical criteria for LATE

Julie A. Schneider, MD, MS *has nothing to disclose.*

Discovery and preclinical development of [¹⁸F]ACI-19626, a first-in-class TDP-43 PET tracer

Tamara Seredenina, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Ac Immune - Salary

New biofluid measures for TDP-43

Aitana Sogorb Esteve, PhD *has nothing to disclose.*

Insights into LATE from postmortem imaging

Paul A. Yushkevich, PhD *has nothing to disclose.*

1-22-FRS-C Comparing plasma biomarkers with PET imaging and neuropathology

Evaluating the interchangeability of blood-based biomarkers and amyloid-PET for identifying patients with Alzheimer's pathology

Samantha C. Burnham, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

CSIRO - Receipt of Intellectual Property Rights/Patent Holder

Eli Lilly and Company - Salary

Diagnostic Performance of Plasma P-tau217, NFL, and GFAP for Predicting Alzheimer's Disease Neuropathology Across Diverse Neurodegenerative Syndromes

Hanna Cho, MD, PhD *has nothing to disclose.*

Utility of Plasma Biomarkers in Screening for Brain Amyloid in the 1Florida Alzheimer Disease Research Center (ADRC)

Ranjan Duara, MD *has nothing to disclose.*

Predicting PET-Based Amyloid and Tau Pathology Stages With Plasma Biomarkers in Alzheimer's disease

Han-Kyeol Kim, MD *has nothing to disclose.*

A head-to-head comparison between plasma p-tau217 and tau-PET for predicting future cognitive decline among cognitively unimpaired individuals

Rik Ossenkoppele, PhD *has nothing to disclose.*

Use of plasma p-tau217 as a pre-screening method for detecting amyloid-PET positivity in cognitively unimpaired participants: A multicenter study

Gemma Salvadó *has nothing to disclose.*

2-13-FRS-B Development of Blood-based Biomarkers for Assessment of Alzheimer's Disease

CSF and Plasma Proteomics in the AT groups. What is beyond amyloid and p-tau?

Andrea L. Benedet, PhD *has nothing to disclose.*

ALZpath pTau217: Multi-cohort performance, cross-assay comparison, and clinical launch for the identification of Alzheimer's Disease pathology

Andreas Jeromin, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ALZpath - Salary

Quanterix - Ownership Interest

Identification of high-performance blood-based biomarkers for early screening and staging of Alzheimer's disease by large-scale plasma proteomic profiling in mild cognitive impairments

Yuanbing JIANG, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cognitact Limited - Ownership Interest

Development of a robust blood-based multi-pathway biomarker assay for early screening and classification of Alzheimer's disease

Li Ouyang, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Plasma Biomarkers for Accelerated Cognitive Decline: A Tool for Targeted Clinical Trial Recruitment

Marc Suarez-Calvet, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Grifols, SL - Consulting Fees

Roche Diagnostics International Ltd - Contracted Research, Consulting Fees

1-12-FRS-B Emerging Biomarkers of Vascular Cognitive Impairment and Dementia: Findings from the MarkVCID Consortium

The ARTS Marker of Arteriolosclerosis: Instrumental and Clinical Validation

Konstantinos Arfanakis, PhD *has nothing to disclose.*

Plasma neurofilament light as a biomarker for vascular contributions to cognitive impairment and dementia.

Tiffany F. Kautz, PhD *has nothing to disclose.*

Cerebrovascular reactivity as a candidate biomarker in small vessel disease related VCID

Hanzhang Lu, PhD *has nothing to disclose.*

White matter free water: a sensitive biomarker of small vascular disease for VCID research

Pauline Maillard, PhD *has nothing to disclose.*

Instrumental and biological validation of PSMD as a VCID biomarker

Claudia L Satizabal, PhD *has nothing to disclose.*

1-21-FRS-C Fluid biomarkers in Lewy body disease

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease

Lyduine E. Collij, PhD *has nothing to disclose.*

Seed amplification assay-determined alpha-synuclein associates with Alzheimer's pathology, clinical symptoms, and cognitive change

Sterling C. Johnson, PhD *has nothing to disclose.*

CSF ATN and α -synuclein co-pathology in AD, PD, and DLB

Marianna Rizzo, MSc *has nothing to disclose.*

Neuroimaging features of CSF α -synuclein seed amplification assay positivity in elderly individuals in AD continuum

Duygu Tosun, PhD *has nothing to disclose.*

Plasma biomarkers in dementia with Lewy bodies: evidence from memory clinic settings

Agathe Vrillon, MD, PhD *has nothing to disclose.*

The MRI signature of alpha-synuclein pathology in preclinical stages and in a memory clinic population

Laura E.M. Wisse, PhD *has nothing to disclose.*

4-11-FRS-B Glial biomarkers and Alzheimer's disease therapeutics

Plasma Biomarkers, Hippocampal Volume and Cognitive Effects of Oral ALZ-801: The Phase 2 Biomarker Study and its Long-Term Extension in APOE4 Carriers with Early Alzheimer's Disease

Susan Abushakra, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheon Inc. -

Plasma GFAP use for population enrichment of clinical trials in preclinical Alzheimer's disease

Bruna Bellaver, PhD *has nothing to disclose.*

Targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in a Phase 1/2 trial to treat people with mild Alzheimer's dementia

Elizabeth E Evans, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Vaccinex - Salary

Microglial activation impacts amyloid- β effects on reactive astrogliosis

João Pedro Ferrari-Souza *has nothing to disclose.*

From glia to cytokine signatures across the Alzheimer's spectrum

Maura Malpetti, PhD *has nothing to disclose.*

2-24-FRS-B Imaging lifespan risk and protective factors for brain and cognition

Association between education and multimodal neuroimaging in men and women across the lifespan

Julie Gonneaud, PhD *has nothing to disclose.*

Imaging the impact of early and late life risk factors on the brain: a comparison

Brian A. Gordon, PhD *has nothing to disclose.*

Adult lifespan neurodegeneration is associated with memory decline independent of amyloid deposition

James M Roe, PhD *has nothing to disclose.*

An experimental approach to disentangle neurodevelopmental and current factors of influence on brain and cognition: an intervention twin study.

Kristine B Walhovd, PhD *has nothing to disclose.*

Functional brain network organization supports cognitive function in patients with Alzheimer's Disease-related pathological burden and brain atrophy

Gagan S Wig, PhD *has nothing to disclose.*

3-30-FRS-C Imaging signatures of LATE

Longitudinal evolution of brain hypometabolism patterns in autopsy-confirmed AD and LATE

Miguel Labrador-Espinosa, MSc *has nothing to disclose.*

Postmortem MRI signature of Hippocampal Sclerosis of Aging

Gustaf Rådman *has nothing to disclose.*

Investigating Spatial Characteristics of Brain Atrophy in Alzheimer's and LATE neuropathology

Khalid Saifullah, BS *has nothing to disclose.*

FDG-PET patterns of LATE & co: disentangling the pathological heterogeneity of Tau-negative amnesic syndromes

Jesús Silva-Rodríguez, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Neurocloud, Qubiotech Health Intelligence SL - Receipt of Intellectual Property Rights/Patent Holder

Limbic predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is associated with lower volume in gray and white matter of the temporal and frontal lobes and basal ganglia: A deformation-based brain morphometry study

Mahir Tazwar *has nothing to disclose.*

Lower amygdala and hippocampal volume correlates with TDP-43 load in limbic-predominant age-related TDP-43 encephalopathy (LATE)

Alex J. Wesseling, MSc *has nothing to disclose.*

3-21-FRS-C Integrating insights from sex stratified analysis, single cell transcriptomics, epigenetics and biomarkers to understand the variability in Lewy body pathology and associated clinical features across the neurodegenerative disease spectrum

Epigenomic assessment of differential pathological and clinical presentation in the Lewy body dementias

Joshua Harvey, BSc *has nothing to disclose.*

Intersection of co-occurring α -synuclein and tau seeds in Lewy body and other neurodegenerative diseases

Allison Kraus, PhD *has nothing to disclose.*

Synuclein Aggregate Assay Performance in Autopsy-Confirmed Lewy Body Dementia: Results from the U.S. Dementia with Lewy Bodies Consortium

James B Leverenz, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Amprion -

GE Healthcare -

Epidemiological and genomic analyses identify drug classes associated with Lewy body dementia

Sonja W Scholz, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cerevel Therapeutics - Contracted Research

Single-cell transcriptomic landscapes of neurodegenerative diseases: towards mapping shared and distinct mechanisms

Elliot Keats Shwab, PhD *has nothing to disclose.*

Presence and Severity of Lewy Body Pathology is Modulated by Sex and ApoE4 Zygosity in a Neuropathologically-Confirmed Alzheimer's Disease Cohort

Mila Valcic, HBSch *has nothing to disclose.*

2-30-FRS-A Longitudinal Biomarker Changes in Down Syndrome Alzheimer Disease

Longitudinal plasma and CSF analyses in Down syndrome. Results from the DABNI cohort

Daniel Alcolea *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Grifols S.A. - Consulting Fees

Longitudinal changes in cognition in relation to PET biomarkers

Sigan L Hartley, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Ionis - Consulting Fees

LuMIND - Consulting Fees

Longitudinal changes in neuroimaging markers of small vessel disease: Implications for clinical trials

Patrick J. Lao, PhD *has nothing to disclose.*

Selection of Biomarkers and Clinical Endpoints for Clinical Trials Targeting Down syndrome-related Alzheimer's disease (DSAD)

Michael Rafii, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consulting Fees

Alzheon - Consulting Fees

Aptah Bio - Consulting Fees

Biohaven - Consulting Fees

Eisai - Contracted Research

Ionis - Consulting Fees

Keystone - Consulting Fees

Lilly - Contracted Research
Positrigo - Consulting Fees

4-21-FRS-C Mapping neurobiological progression through imaging subtypes

A generalizable data-driven model of atrophy heterogeneity and progression in a memory clinic setting

Hannah Baumeister, MSc *has nothing to disclose.*

Data-driven analysis of 10,361 amyloid-PET scans from the IDEAS study reveals two primary axes of variation

Joseph Giorgio, PhD *has nothing to disclose.*

Differential network-based propagation of cortical thinning in atrophy subtypes in non-demented individuals

Luigi Lorenzini, MSc *has nothing to disclose.*

Event-based modeling of T-N *mismatch* reveals distinct spatio-temporal trajectories of subtypes with likely co-pathology in Alzheimer's disease

Xueying Lyu *has nothing to disclose.*

Data-driven progression patterns of A β , tau, α -synuclein and vascular pathology in a clinical population

Sophie E. Mastenbroek, MSc *has nothing to disclose.*

Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer's disease

Wiesje Pelmans, PhD *has nothing to disclose.*

3-29-FRS-C Navigating the Tau Pathway: Insights into Aging, Dementia, and Alzheimer's Disease using tau PET

Quantification of tau pathology in the basal forebrain: Associations with age, amyloid, brain structure and cognition

Trevor Chadwick, BA *has nothing to disclose.*

Estimating the time between A β positivity and elevated regional tau in preclinical AD

William Coath, MSc *has nothing to disclose.*

The prevalence of tau-PET positivity in aging and dementia

Emma M. Coomans, PhD *has nothing to disclose.*

Generalizability of demographic and genetic variable interactions with amyloid driving tau burden in a heterogeneous group of cognitively normal older adults: A multi-cohort study

Theresa M. Harrison, PhD *has nothing to disclose.*

Linking the estimated time of onset of low locus coeruleus integrity to the estimated time of onset of elevated entorhinal tau

Heidi I.L. Jacobs, PhD *has nothing to disclose.*

Novel regional flortaucipir visual read approaches to stratify subjects by tau spread: Evaluation in TRAILBLAZER-ALZ 2 phase 3 study of donanemab

Ian Kennedy, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly & Company - Salary

2-21-FRS-C Strategies for clinical integration of Alzheimer's biomarkers

Optimizing tau-PET referrals in memory clinics through a blood biomarker workflow

Wagner Scheeren Brum, MD *has nothing to disclose.*

Early Identification of Alzheimer's Disease with a Machine Learning-Enabled Digital Cognitive Assessment: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status

Ali Jannati, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Linus Health - Salary

Considerations for implementation of Alzheimer's disease blood-based biomarkers in clinical care based on recently updated NIA-AA criteria

Michelle M. Mielke, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consulting Fees

Eli Lilly - Consulting Fees

Roche - Consulting Fees

Pragmatic considerations in clinical biomarker testing for Alzheimer disease

Suzanne E. Schindler, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consulting Fees

Using a blood-based biomarker panel for Alzheimer's disease to determine eligibility for disease modifying treatment in a memory clinic setting: three scenarios

Sinthujah Vigneswaran, MD *has nothing to disclose.*

Real world implementation of blood biomarkers in primary care

Deanna R Willis, MD, MBA *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Resonea (sleep apnea device company) - Ownership Interest

1-30-FRS-A The Atypical Alzheimer's Disease Continuum: from Clinical Phenotypes to Disease Mechanisms

Latent atrophy factors in Primary Progressive Aphasia due to Alzheimer's disease and linguistic features, across different cultural settings.

Ismael Luis Calandri, MD *has nothing to disclose.*

Clinicoradiologic correlates of corticolimbic index (CLix) and glial activation differences among neuropathologic subtypes of Alzheimer's disease

Sara R Dunlop, BSc *has nothing to disclose.*

Alzheimer's disease subtypes based on cerebrospinal fluid proteomics have distinct CSF lipid profiles.

Betty M. Tijms, PhD *has nothing to disclose.*

Visual and body perceptual disturbances in posterior cortical atrophy and Alzheimer's disease

Keir X X Yong, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Roche - Consulting Fees

4-31-PER-B Translating AD biomarkers into clinical practice in an era of precision medicine

Recent advances and clinical implementations of blood biomarkers

Nicholas J. Ashton, PhD *has nothing to disclose.*

Diversity considerations in implementing biomarkers in clinical practice

Gladys E. Maestre, MD, PhD *has nothing to disclose.*

Implementing tau and amyloid PET in clinical practice

Gil D. Rabinovici, MD *has nothing to disclose.*

The use of biomarkers in anti-amyloid treatment

Steve Salloway *has nothing to disclose.*

Blood and CSF biomarkers in AD diagnostics and disease stratification

Inge M.W. Verberk, PhD *has nothing to disclose.*

4-32-FRS-C Clinical trial results and design considerations

The Alzheimer's Tau Platform (ATP): a Phase 2, combination amyloid and tau therapy clinical trial for early AD

Adam L. Boxer, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees
Amylyx - Consulting Fees
Arkuda - Consulting Fees
Arrowhead - Consulting Fees
Arvinas - Consulting Fees
Eli Lilly - Consulting Fees
Muna Therapeutics - Consulting Fees
Oscotec - Consulting Fees
Pfizer - Consulting Fees
Switch - Consulting Fees
Transposon - Consulting Fees
UnlearnAI - Consulting Fees

The role of imaging in outcomes and safety monitoring for preclinical intervention studies.

Michael Rafii, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consulting Fees
Alzheon - Consulting Fees
Aptah Bio - Consulting Fees
Biohaven - Consulting Fees
Eisai - Contracted Research
Ionis - Consulting Fees
Keystone - Consulting Fees
Lilly - Contracted Research
Positrigo - Consulting Fees

Efficacy and safety evaluation of type-3 phosphodiesterase inhibitor Cilostazol in mild cognitive impairment

Satoshi Saito, MD, PhD *has nothing to disclose.*

Looking to the future: How can clinical trials be designed in partnership with our participants?

Jonathan M Schott, MD FRCP *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Consulting Fees

Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer's disease

Wiesje M. van der Flier, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen MA Inc - Consulting Fees
Biogen MA Inc, - Consulting Fees
Danone -
Eisai - Consulting Fees
Eli Lilly - Consulting Fees
European Brain Council -
Novo Nordisk -
NovoNordisk evoke/evoke+. -
Oxford Health Policy Forum CIC - Consulting Fees
Roche - Consulting Fees
Springer Healthcare -
WebMD Neurology (Medscape) -

The effects of the novel phosphodiesterase 9 (pde9) inhibitor E2027 (irsenontrine) on CSF proteomics profile in amyloid positive and amyloid negative Lewy Body Dementia

Lisa Vermunt, PhD MD *has nothing to disclose.*

2-12-FRS-C Underlying mechanisms and biomarkers of vascular pathology

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

Ilana Caro *has nothing to disclose.*

Modelling Small Vessel Disease Using Regional MRI Markers, and Mediating Effects on Cognitive Decline

Sokratis Charisis, MD *has nothing to disclose.*

Plasma Proteomic Determinants of Small Vessel Disease of the Brain: the Multi-Ethnic Study of Atherosclerosis

Rizwan Kalani, MD *has nothing to disclose.*

Cerebrovascular reactivity (CVR) MRI as a biomarker for cerebral small vessel disease (SVD) related cognitive decline: Multi-site validation in the MarkVCID Consortium

Peiying Liu, PhD *has nothing to disclose.*

Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer's disease in a diverse cohort

Samuel N. Lockhart, PhD *has nothing to disclose.*

Longitudinal interplay between cerebral glucose metabolism, subclinical atherosclerosis and cardiovascular risk factors in midlife: the PESA study

Catarina Tristão-Pereira *has nothing to disclose.*

1-31-PER-A White matter lesions in Alzheimer's Disease: heterogeneity of pathophysiology and clinical consequences at the era of anti-amyloid drugs

Does the association between white matter hyperintensity severity and Alzheimer's disease indicate a primary role of cerebrovascular disease in Alzheimer's disease pathogenesis?

Adam M. Brickman, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cognition Therapeutics - Consulting Fees

Cognito - Consulting Fees

CogState - Consulting Fees

WMH and AD: is CAA the missing piece? Potential consequences at the anti-amyloid era.

Andreas Charidimou, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Imperative Care - Consulting Fees

Can neuroimaging methods help us to disentangle WMH etiology in AD?

Mahsa Dadar, PhD *has nothing to disclose.*

All WMH are not of purely vascular origin: existence of AD-related WMH.

Antoine Garnier-Crussard, MD, MSc *has nothing to disclose.*

1-24-FRS-C Cognition, behavior, and gait

Early identification of participants at risk of cognitive decline: An online tool for patient prediction of cognitive decline.

Marcela Ines Cespedes, PhD *has nothing to disclose.*

Mild Behavioral Impairment is associated with incident cognitive decline among dementia-free, racially diverse older adults: Data from the African Americans Fighting Alzheimer's in Midlife (AA-FAIM) study.

Barbara L. Fischer, PsyD *has nothing to disclose.*

Physical function and cognition in older adult women: the Study of Women's Health Across the Nation (SWAN)

Carrie A. Karvonen-Gutierrez, PhD, MPH *has nothing to disclose.*

Exploring relationships among neuropsychiatric symptoms, subjective cognitive complaints, cognitive performance, and incident dementia: Findings from the Sydney Memory and Ageing Study

Katya T. Numbers, PhD *has nothing to disclose.*

Examination of intrapersonal and affective characteristics associated with everyday function among older adults with subjective cognitive decline

Sarah Tomaszewski Farias, PhD *has nothing to disclose.*

Sleep quality trajectories and motoric cognitive risk syndrome among Chinese rural older adults: Does gender matter?

Dan Zhao, PhD *has nothing to disclose.*

3-25-FRS-B Dialogues of the Brain: Understanding Dementia in a Multilingual Context

Language switching and executive control in bilinguals with Mild Cognitive Impairment

Marco Calabria, PhD *has nothing to disclose.*

Enhancing Cognitive Health in Aging through New Language Acquisition: Insights from Behavioral and Neuroimaging Studies

Ladan Ghazi Saidi *has nothing to disclose.*

Association of Majority versus Minority First Language Multilingualism and Socioeconomic Status on Cognition among Older Indian Adults

Iris M. Strangmann, PhD *has nothing to disclose.*

Diversity in Sociodemographic and Linguistic landscape: Perspectives from Chinese American, Mexican American, and Indian Cohorts

Boon Lead Tee, MD, MS *has nothing to disclose.*

Bilingualism and education may have distinct reserve/resilience trajectories: Evidence from white matter changes

Nithin Thanissery, M Sc *has nothing to disclose.*

1-34-PER-B Digital Biomarkers

Digital cognitive testing

Rebecca E Amariglio, PhD *has nothing to disclose.*

Validation of digital biomarkers

Rhoda Au, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Davos Alzheimer's Collaborative - Consulting Fees

NovoNordisk - Consulting Fees

Signant Health - Consulting Fees

Human-robot interactions in MCI

Yu-Ling Chang, PhD *has nothing to disclose.*

Digital biomarkers in clinical trials

Jason J. Hassenstab, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AlzPath - Consulting Fees

Prothena - Consulting Fees

Novel digital speech biomarker for early detection of Alzheimer's disease

Alexandra König, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ki:elements - Ownership Interest

1-16-FRS-C Digital Phenotyping of Speech and Language in Alzheimer's Disease and Related Dementias

Characterization of Language Profiles in Cognitively-Defined Subgroups of Alzheimer's Disease

Jeanne Gallée, PhD *has nothing to disclose.*

A framework for automated speech and language analysis in Spanish-speaking Latinos

Adolfo M. Garcia, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

TELL Toolkit SA - Ownership Interest

Identification of underlying AD pathology in cognitively unimpaired individuals with subjective cognitive decline by the means of automated speech and language processing

Nicklas Linz, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ki:elements - Salary

Into the Visual World of Patients with Posterior Cortical Atrophy through their Words: A Natural Language Processing Approach

Neguine Rezaii, MD *has nothing to disclose.*

Development and validation of language as an endpoint in Alzheimer's Disease clinical trials

William Simpson, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cambridge Cognition - Salary

Multi-day at-home assessments of speech acoustics in Dutch cognitively normal adults with-and without AD pathology

Rosanne L. van den Berg, MA *has nothing to disclose.*

2-25-FRS-A Examining Mild Behavioural Impairment across the neurodegenerative and geographical spectrum: associations with cognition, biomarkers and functional connectivity

Five-year Trajectory of Mild Behavioral Impairment in People with Subjective Cognitive Complaints

Byron Creese, PhD *has nothing to disclose.*

Baseline regional amyloid distribution in relation to subsequent self- and informant-rated apathy scores in community-dwelling older adults

Catherine E Munro, PhD *has nothing to disclose.*

Brain functional connectivity and neuropsychiatric symptoms in patients with mild cognitive impairment, cerebrovascular disease and Parkinson disease

Neda Rashidi-Ranjbar, MD, PhD *has nothing to disclose.*

Associations among mild behavioral impairment symptoms, brain pathology and cognition in individuals with autosomal-dominant Alzheimer's disease: Findings from the Colombia-Boston (COLBOS) biomarker study

Daniel Vasquez, MD *has nothing to disclose.*

1-33-FRS-C Hearing and olfaction

Midlife Sensory and Motor Measures Among Best Predictors in Parsimonious Models of Long-Term Cognitive Decline and Onset of Cognitive Impairment in Middle-Aged Adults

Natascha Merten, PhD, MS *has nothing to disclose.*

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using MR-PET

Hossein Moein Taghavi, BA *has nothing to disclose.*

Addressing the Unmet Hearing Care Needs of Persons Living with Cognitive Impairment: A Qualitative Study of End-Users, Care Partners, and Experts

Carrie L Nieman, MD, MPH *has nothing to disclose.*

Alterations in brain structure and functional connectivity associated with hearing loss and olfactory loss

Natalie Phillips, PhD *has nothing to disclose.*

Effect of hearing intervention on three-year change in brain morphology

James Russell Pike, MBA *has nothing to disclose.*

Discussion and Documentation of Hearing Difficulty by Providers in the Presence of Cognitive Concerns- study of the Medicare Annual Wellness Visit and Medial Record

Danielle Powell, AuD PhD *has nothing to disclose.*

5-16-FRS-C Cognitive manifestations in pre-clinical AD

Associations Between Speech-based Biomarkers of Cognition and Traditional Neuropsychological Assessments in a Preclinical AD Cohort

Zampeta-Sofia Alexopoulou, MSc *has nothing to disclose.*

Cognitive dynamics in preclinical and very mild Alzheimer disease

Andrew J. Aschenbrenner, PhD *has nothing to disclose.*

Leveraging a multi-day learning paradigm to reveal early amyloid- and tau- related cognitive deficits in preclinical Alzheimer's disease

Roos J Jutten, PhD *has nothing to disclose.*

Learning deficits in late middle-aged *APOE* ε4 carriers: Implications for emergent Alzheimer's disease

Yen Ying Lim, PhD *has nothing to disclose.*

Decreased practice effects in preclinical Alzheimer's disease: a multicenter, longitudinal, cohort study

Adrià Tort-Merino *has nothing to disclose.*

Amyloid-positivity is characterized by decline in semantic fluency: An in-depth investigation of verbal fluency trajectories, item-level characteristics and its prognostic value in patients with subjective cognitive decline

Rosanne L. van den Berg, MA *has nothing to disclose.*

4-16-FRS-C Understanding the relationships between sleep, cognitive decline, and dementia

Disrupted Sleep at Night Is Associated with a Higher Level of Agitation Throughout the Week in People Living with Cognitive Decline

Wan-Tai M Au-Yeung, PhD *has nothing to disclose.*

Subcortical correlates of sleep across Alzheimer's Disease and cognitively healthy adults: an in vivo study

Neus Falgàs Martínez, MD, PhD *has nothing to disclose.*

Shift and night work in the fourth decade is associated with reduced brain volume in late life independent of amyloidogenic pathways: an Insight 46 study

Josh King-Robson, BSc, MRCP *has nothing to disclose.*

Potential of dual orexin receptor antagonists to prevent Alzheimer's disease

Brendan P Lucey, MD, MSCI *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Beacon Biosignals - Consulting Fees

Eisai - Consulting Fees, Contracted Research

Eli Lilly - Consulting Fees

GLG Group - Consulting Fees

Merck -

OrbiMed - Consulting Fees

Relationships between locus coeruleus microstructural integrity, sleep, and 24-h rest-activity rhythm in the context of plasma markers of Alzheimer's disease: a 7T MRI study of asymptomatic older individuals

Maxime Van Egroo, PhD *has nothing to disclose.*

Mechanisms underlying AD-sleep interactions: Recent insight from animal models

Sigrid C Veasey, MD *has nothing to disclose.*

4-34-FRS-C Women's health

Evidence for a protective effect of hormone replacement therapy on Alzheimer's disease neuropathological and clinical outcomes across cohorts

Jennifer Bruno, PhD *has nothing to disclose.*

The associations between *CYP19A1* polymorphisms and serum 17 β -estradiol levels in Chinese patients with Alzheimer's disease

Lu hua Chen, MD, PhD *has nothing to disclose.*

Early menopause and cognitive impairment: Insights from the ELSI-Brazil Study

Alvaro de Oliveira Franco, MD *has nothing to disclose.*

Prospective Study of Endogenous Estrogen History and Cognitive Decline in the Nurses' Health Study

Namuunaa Juramt, MPH *has nothing to disclose.*

Influence of menopause on cognitive performance in aging Indian women: A cross-sectional study

Hitesh Pradhan, MSc *has nothing to disclose.*

Sex hormones and white matter hyperintensities in midlife women in the MsBrain study

Rebecca C Thurston, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Astellas - Consulting Fees

Bayer - Consulting Fees

Hello Therapeutics - Consulting Fees

2-36-PER-C Dementia and Emergency Care: Directions, Opportunities, and Future Considerations

ED care and Amyloid-Related Imaging Abnormalities - Impact and Future research

Neelum T. Aggarwal, MD *has nothing to disclose.*

GEAR 2.0 - Communication and Shared Decision Making

Christopher R Carpenter, MD, MSc *has nothing to disclose.*

GEAR 2.0 - Emergency Care Practices

Scott M Dresden, MD, MS *has nothing to disclose.*

ED-to-community care transitions for persons living with dementia

Cameron Gettel, MD, MHS *has nothing to disclose.*

GEAR 2.0 - Detection of Dementia and Cognitive Impairment

Ula Hwang, MD, MPH *has nothing to disclose.*

GEAR 2.0 - Care Transitions

Manish N Shah, MD, MPH *has nothing to disclose.*

3-27-FRS-C Dementia Care in Long-term Care and Health Systems

Evaluating the potential of teleneurology in a low-resource setting for dementia: An exploratory study on patient and healthcare provider satisfaction

Pullumpallil Thomas Alexander, MD, DM *has nothing to disclose.*

Multispecialty Interprofessional Team (MINT) Memory Clinic Overview and Data From Spread Across Canada

Linda Lee, MD *has nothing to disclose.*

Fostering the delivery of non-pharmacological nursing home dementia care: Designing and executing a multi-site pragmatic clinical trial

Natalie E Leland, PhD *has nothing to disclose.*

Understanding Family Caregiver Experience and Satisfaction with Nursing Home Care: A Conceptual Model

Catherine V Piersol, PhD, OTR/L *has nothing to disclose.*

A cluster randomized trial: Exploratory quantitative analysis comparing resident outcomes for two approaches to promote non-pharmacological, resident-centered dementia care in nursing homes

Victoria Shier, PhD *has nothing to disclose.*

Pragmatic Implementation of a Comprehensive Dementia Care Management Program in a Large Health System: The Cedars-Sinai C.A.R.E.S. Program Preliminary Data

Zaldy S Tan, MD, MPH *has nothing to disclose.*

3-16-FRS-C A focus on diverse culture, identity and context in dementia care and caregiving research

“They are perceived to be witches, and some are killed”: Community perceptions of elderly people living with Dementia in Kilifi, A Coastal County in Kenya.

Andrew Okoth Aballa, MSc *has nothing to disclose.*

Digital Elder Abuse Intervention for Early Detection of Abuse in Older Adults Living with Dementia

Fuad Abujarad, PhD, MSc *has nothing to disclose.*

Sharing Roles in Home Care: Family Care Partners and Paid Caregivers

Chanee D Fabius, PhD *has nothing to disclose.*

Engaging Sexual and Gender Minority Caregivers of Alzheimer’s and Related Dementias: The RISE Project

Jason D. Flatt, PhD, MPH *has nothing to disclose.*

Behaviour support planning in residential aged care - pilot to explore implementation of new legislation in Australia

Jacqueline Wesson, PhD *has nothing to disclose.*

2-9-FRS-D Current directions in testing and implementation for dementia diagnosis and care I

Differences in referral source across racial and ethnic groups at Alzheimer's Disease Research Centers

Carol Chan, MBBCh, MSc *has nothing to disclose.*

Does virtual reality increase the emotional well-being benefits of online psychoeducation? Preliminary results in informal caregivers of people with Alzheimer's disease.

Cristina Festari, MS, PhD *has nothing to disclose.*

Unmet Needs in the Diagnosis and Management of Early AD in Community-Based Settings in the United States

Feride H Frech, PhD, MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eisai Inc. - Salary

3-9-FRS-D Current directions in testing and implementation for dementia diagnosis and care II

Gait speed as a surrogate marker of change in cognitive function derived from multimodal lifestyle intervention: J-MINT study

Kosuke Fujita, PhD *has nothing to disclose.*

Altered Cerebral Blood Flow as a Screening Test for Neurodegenerative Disease: A Comparative Analysis of Arterial Spin Labeled Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography

Andres Ricaurte Fajardo, MD *has nothing to disclose.*

Neural Imaging for Alzheimer's Prediction using AI: Exploring CNNs and LIME Explanations

Abraham Varghese, PhD *has nothing to disclose.*

3-36-FRS-C Effective strategies to improve care among care partners of PLWD

Impact of State-Level Equity Indices on Psychosocial Outcomes Among Sexual and Gender Minority Caregivers of People with Alzheimer's Disease and Related Dementias

Joel G Anderson, PhD, CHTP, FGSA *has nothing to disclose.*

Home-based family caregiver-delivered music and reading interventions for people living with dementia (HOMESIDE trial): an international randomised controlled trial

Felicity Baker, PhD *has nothing to disclose.*

Enhancing Dementia Care: A Digitally Supported Care Management Program for Informal Caregivers - A Cluster-Randomized Controlled Trial

Melanie Boekholt, M.A. *has nothing to disclose.*

Impacts of an Exercise and Behavioral Intervention on Community-Dwelling Older Adults with Dementia and Their Family Caregivers in Thailand

Hongtu Chen, PhD *has nothing to disclose.*

Applying the eHealth Literacy lens to evaluate a virtual assistant to support family carers of people with dementia

Tuan Anh Nguyen, PhD *has nothing to disclose.*

The Effective Strategies Program for Dementia Care Partners (ESP-C): A Pilot Study

Shannon Reilly, PhD *has nothing to disclose.*

3-36-FRS-C Effective strategies to improve care among care partners of PLWD

Impact of State-Level Equity Indices on Psychosocial Outcomes Among Sexual and Gender Minority Caregivers of People with Alzheimer's Disease and Related Dementias

Joel G Anderson, PhD, CHTP, FGSA *has nothing to disclose.*

Home-based family caregiver-delivered music and reading interventions for people living with dementia (HOMESIDE trial): an international randomised controlled trial

Felicity Baker, PhD *has nothing to disclose.*

Enhancing Dementia Care: A Digitally Supported Care Management Program for Informal Caregivers - A Cluster-Randomized Controlled Trial

Melanie Boekholt, M.A. *has nothing to disclose.*

Impacts of an Exercise and Behavioral Intervention on Community-Dwelling Older Adults with Dementia and Their Family Caregivers in Thailand

Hongtu Chen, PhD *has nothing to disclose.*

Applying the eHealth Literacy lens to evaluate a virtual assistant to support family carers of people with dementia

Tuan Anh Nguyen, PhD *has nothing to disclose.*

The Effective Strategies Program for Dementia Care Partners (ESP-C): A Pilot Study

Shannon Reilly, PhD *has nothing to disclose.*

2-16-PER-A Dementia and The Provision of Care: Diverse Lived Experiences Across The Black/African Diaspora

Risk factors and treatment associated with dementia among Black persons in Latin America

Raphael Machado Castilhos, MD, PhD *has nothing to disclose.*

Aging among Afro-Caribbeans: Insights across the research process, from conceptualization, outreach, and cognitive measurement to analysis and Interpretation

Stephanie Chrisphonte *has nothing to disclose.*

The impact of stigma on the provision and coordination of dementia care

Roxanne Jacobs, PhD *has nothing to disclose.*

The impacts of lifestyle and environmental factors on dementia risk and care

Kwaku Poku Asante *has nothing to disclose.*

3-33-FRS-C Examining dementia lived experiences and trajectories via structural and social perspectives

Neural underpinnings of cognitive resilience in Brazilian SuperAgers

Wyllians Vendramini Borelli, MD, PhD *has nothing to disclose.*

National Estimates of Incremental Work Absenteeism Costs Associated with Adult Children of Parents with Alzheimer's Disease and Related Dementias

Seyeon Jang, MS *has nothing to disclose.*

Multilevel measures of socioeconomic disparities impact brain health and dementia across the Americas

Agustina Legaz, PhD *has nothing to disclose.*

Using community health workers to assess the prevalence of dementia in a community based sample of older Zambians

Mataa M Mataa, MBChB *has nothing to disclose.*

Policy & Organizational Factors that Affect the Utilization of Health Services for Alzheimer's Disease Among the Latinx Community – The Primary Care Provider Perspective

Maria C Mora Pinzon, MD, MS *has nothing to disclose.*

Does education years delay Alzheimer's disease in cognitively normal oldest old?

Hamid R Sohrabi, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alnylam - Contracted Research

Biogen - Contracted Research

1-28-FRS-C Lancet standing commission on dementia prevention, intervention, and care. Scientific advances in the 2024 commission.

Diversity, Equity and Inclusivity- Lower and Middle Income countries and the Lancet commission

Cleusa P Ferri, PhD *has nothing to disclose.*

Potentially modifiable risk factors for dementia putting the evidence together: Total population attributable fraction.

Gill Livingston, MD *has nothing to disclose.*

Triangulation to make decisions about what are modifiable risk factors and the new risk factors

Naaheed Mukadam, BMBCh, MRCPsych, MA, MSc, PhD *has nothing to disclose.*

Biomarkers and their place in dementia research and practice- the lancet commission recommendations

Lon S. S. Schneider, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consulting Fees

Athira - Consulting Fees

Biogen - Contracted Research

BioVie - Consulting Fees

Eisai - Contracted Research

Eli Lilly - Contracted Research

Immunobrain Checkpoint, Ltd - Consulting Fees

Lighthouse - Consulting Fees

Linus Health - Consulting Fees

Merck - Consulting Fees

Muna - Consulting Fees

Novo Nordisk - Consulting Fees

Roche/Genentech - Contracted Research

Synaps Dx - Consulting Fees

Washington University in St. Louis - Contracted Research

Interventions for cognitive symptoms of dementia - and the Lancet commission view on anti-amyloid antibodies

Geir Selbaek, PhD, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consulting Fees

Interventions for people living with dementia: updates from 2024 Lancet Commission

Andrew Sommerlad, MBBS, PhD *has nothing to disclose.*

3-23-FRS-A Recruitment for Alzheimer's Studies in LMICs: Challenges and Opportunities for Engagement of High-Risk Populations

LatAm-FINGERS: Navigating Diversity in the Engagement of a Subcontinental Trial for Dementia Prevention.

Ismael Luis Calandri, MD *has nothing to disclose.*

LATE-LIFE EDUCATION IMPROVES ADULT EXECUTIVE FUNCTION: THE PROAME TRIAL

Clarisse Vasconcelos Friedlaender, Bachelor *has nothing to disclose.*

READD-ADSP Kenya: Opportunities for recruitment of participants for Alzheimer's Disease genetic research in Sub-Saharan Africa

Christine W. Musyimi, PhD *has nothing to disclose.*

MIND-China in 2018-2023: Multimodal interventions in rural communities

Chengxuan Qiu, PhD *has nothing to disclose.*

2-PL Plenary Session

From Longevity to Vulnerability: Genomic Pathways Underlying Cognitive Health in Centenarians and Neurodegenerative Disease

Henne Holstege, PhD *has nothing to disclose.*

Antisense oligonucleotide therapeutics for neurodegenerative diseases

Timothy Miller, MD, PhD *has nothing to disclose.*

3-19-FRS-A Beyond Amyloid Removal with Lecanemab Treatment: Update on Long-Term Imaging and Fluid Biomarkers

Lecanemab Slows Tau PET Accumulation

Arnaud Charil, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc. - Salary

"Paradoxical" Cerebral Volume Changes in Anti-Amyloid Immunotherapy Trials

Nick C Fox, MD, PhD *has nothing to disclose.*

Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model

Larisa Reyderman, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc. - Salary

Long-Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma

Charlotte E. Teunissen, PhD *has nothing to disclose.*

2-4-FRS-D Clinical trial analysis strategies I

Study entry, change, and death: learning from decades of follow-up in clinical-pathologic studie

Ana W. Capuano, Ph.D. *has nothing to disclose.*

Time-based measures for quantifying disease modification in Alzheimer's disease

Lars Lau Raket, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Salary

Improve Statistical Efficacy Inference: Global Reduction Rate in Disease Progression

Guoqiao Wang, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Eli Lilly and Company - Consulting Fees

5-5-FRS-D Clinical trial analysis strategies II

Understanding sex differences in neuroimaging biomarkers and clinical trials

Rachel F. Buckley, PhD *has nothing to disclose.*

Leveraging biofluid markers as a real-time window to understand molecular drivers of sex differences in AD clinical trials

Kaitlin B. Casaletto, PhD *has nothing to disclose.*

Real-world effectiveness of anti-amyloid therapies: the feasibility of obtaining historic controls from large-scale disease registries

Linus Jönsson, MD MSc PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

H. Lundbeck A/S - Consulting Fees

Janssen Pharmaceutica - Receipt of Intellectual Property Rights/Patent Holder

Novo Nordisk A/S - Contracted Research

5-5-FRS-D Clinical trial analysis strategies II

Understanding sex differences in neuroimaging biomarkers and clinical trials

Rachel F. Buckley, PhD *has nothing to disclose.*

Leveraging biofluid markers as a real-time window to understand molecular drivers of sex differences in AD clinical trials

Kaitlin B. Casaletto, PhD *has nothing to disclose.*

Real-world effectiveness of anti-amyloid therapies: the feasibility of obtaining historic controls from large-scale disease registries

Linus Jönsson, MD MSc PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

H. Lundbeck A/S - Consulting Fees

Janssen Pharmaceutica - Receipt of Intellectual Property Rights/Patent Holder

Novo Nordisk A/S - Contracted Research

4-32-FRS-C Clinical trial results and design considerations

The Alzheimer's Tau Platform (ATP): a Phase 2, combination amyloid and tau therapy clinical trial for early AD

Adam L. Boxer, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Amylyx - Consulting Fees

Arkuda - Consulting Fees

Arrowhead - Consulting Fees

Arvinas - Consulting Fees

Eli Lilly - Consulting Fees

Muna Therapeutics - Consulting Fees

Oscotec - Consulting Fees

Pfizer - Consulting Fees

Switch - Consulting Fees

Transposon - Consulting Fees

UnlearnAI - Consulting Fees

The role of imaging in outcomes and safety monitoring for preclinical intervention studies.

Michael Rafii, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consulting Fees

Alzheon - Consulting Fees

Aptah Bio - Consulting Fees

Biohaven - Consulting Fees

Eisai - Contracted Research

Ionis - Consulting Fees

Keystone - Consulting Fees

Lilly - Contracted Research

Positriago - Consulting Fees

Efficacy and safety evaluation of type-3 phosphodiesterase inhibitor Cilostazol in mild cognitive impairment

Satoshi Saito, MD, PhD *has nothing to disclose.*

Looking to the future: How can clinical trials be designed in partnership with our participants?

Jonathan M Schott, MD FRCP *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Consulting Fees

Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer's disease

Wiesje M. van der Flier, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen MA Inc - Consulting Fees

Biogen MA Inc, - Consulting Fees

Danone -

Eisai - Consulting Fees

Eli Lilly - Consulting Fees

European Brain Council -

Novo Nordisk -

NovoNordisk evoke/evoke+ -

Oxford Health Policy Forum CIC - Consulting Fees

Roche - Consulting Fees

Springer Healthcare -

WebMD Neurology (Medscape) -

The effects of the novel phosphodiesterase 9 (pde9) inhibitor E2027 (irsenontrine) on CSF proteomics profile in amyloid positive and amyloid negative Lewy Body Dementia

Lisa Vermunt, PhD MD *has nothing to disclose.*

3-31-PER-A Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer's Disease?

Neuro-Dynamic Quantitative Systems Pharmacology (Qsp) Model Supports Continued Lecanemab Treatment With Maintenance Dosing For Alzheimer's Disease

Youfang Cao, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc. - Salary

How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing?

Larisa Reyderman, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing?

Dennis J. Selkoe, MD *has nothing to disclose.*

Is there Evidence for a Continued Benefit for Long-Term Lecanemab Treatment? A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data

Christopher H van Dyck, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Contracted Research

1-32-FRS-B Drug development clinical trial results

Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Candace Andersson, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Axsome Therapeutics - Ownership Interest

Escitalopram for Agitation in Alzheimer's Dementia

Tarek K Rajji, MD *has nothing to disclose.*

Results from a Phase 2a Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Lomecel-B™ in Mild Alzheimer's Disease Dementia

Kevin N. Ramdas, MD, MPH *has nothing to disclose.*

Blarcamesine in Early Alzheimer Disease Phase 2b/3 Randomized Clinical Trial

Marwan N. Sabbagh, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheon - Ownership Interest

Anavex - Consulting Fees

Cognito Therapeutics - Consulting Fees

Eisai - Consulting Fees

KeiferRx - Consulting Fees

Lilly - Consulting Fees

NeuroTau - Ownership Interest

NeuroTherapia - Consulting Fees

Novo Nordisk - Consulting Fees

Prothena - Consulting Fees

Roche - Consulting Fees

Signant - Consulting Fees

Synaptogenix - Consulting Fees

T3D - Consulting Fees

Exploratory clinical outcomes from BIIB080 (MAPT ASO) phase 1b multiple ascending dose and long-term extension study in mild Alzheimer's disease

Melanie Shulman, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Salary, Ownership Interest

2-14-PER-A Future perspectives on how to conduct clinical trials in Alzheimer's Disease: Where do we go from here?

Non-pharmacological approaches

Laura D Baker, PhD *has nothing to disclose.*

Alternatives to placebo-controlled clinical trials - basket trials, digital twins, external controls

Suzanne B. Hendrix, Ph.D *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pentara Corporation - Ownership Interest

Combination therapies

Eric McDade, DO *has nothing to disclose.*

Surrogate endpoints - clinical and analytical considerations for maximal utility in trial design, drug development and regulatory decision making

Geert Molenberghs, PhD *has nothing to disclose.*

2-31-PER-C Insights into structure and function of gamma-secretases lead to precision medicine in Alzheimer Disease

Modulating γ -secretase activity to make precision medicine for AD

Lucia Chávez-Gutiérrez, PhD *has nothing to disclose.*

Gamma-secretase modulation: from bench to clinic

Irene Gerlach, PhD *has nothing to disclose.*

targeting gamma-secretase in the Dominantly Inherited AD patients

Eric McDade, DO *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consulting Fees

Alzamend - Consulting Fees

Merck - Consulting Fees

Roche - Consulting Fees

Washington University - Receipt of Intellectual Property Rights/Patent Holder

what would be needed to start a real primary prevention trial in Alzheimer's Disease

Catherine J Mummery, MD, PhD *has nothing to disclose.*

gamma-secretase modulation: from bench to clinic

Rudolph E. Tanzi, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acta Pharmaceuticals - Consulting Fees, Royalty, Ownership Interest

Structural Mechanism of γ -secretase Cleavage and Regulation

Rui Zhou, PhD *has nothing to disclose.*

1-23-FRS-B International Practices for Inclusive ADRD Clinical Trial Recruitment

Inclusive Clinical Trials in Alzheimer's Disease: A Latin American Perspective from LatAm FINGERS

Lucia Crivelli, PhD *has nothing to disclose.*

Alzheimer's and Related disorders Multicenter Archive (ARMA): a collaborative platform to advance ADRD diagnosis and treatment in Spain

Ignacio Illán-Gala *has nothing to disclose.*

Inclusive Approaches To Promote Participation of Diverse Demographic Groups in Preclinical AD Clinical Trials Through Centralized Recruitment.

Doris P. Molina Henry, PhD. *has nothing to disclose.*

Strategies and challenges for recruiting and retaining illiterate older adults with low socioeconomic levels in a non-pharmacological trial: the PROAME study

Elisa de Paula França Resende, MD, PhD *has nothing to disclose.*

Recruitment for ADRD Clinical Trials Optimized through Academic and Community Partnership in Appalachia

Elizabeth K. Rhodus, PhD, OTR/L *has nothing to disclose.*

4-30-PER-C Lewy body dementias: Challenges and opportunities in the era of biomarkers

The Alzheimer's Association Revised Criteria for Diagnosis and Staging of Alzheimer's Disease – Where does Lewy body dementia stand?

Carla Abdelnour, MD, PhD *has nothing to disclose.*

Clinical outcome assessments for LBD trials – Should we borrow?

Brad F. Boeve, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cambridge University Press - Royalty

LBD around the world – The Latin American experience

Miguel Germán Borda, MD, PhD *has nothing to disclose.*

AD pathology in LBD – Implications for Clinical Trials

Bhavana Patel, DO *has nothing to disclose.*

The Neuronal Synuclein Disease Integrated Staging System -- Opportunities to advance Lewy body dementia research

Kathleen L. Poston, MD, MS *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Amprion - Ownership Interest

Biohaven - Consulting Fees

Curasen - Ownership Interest

Neuron23 - Consulting Fees

Novartis - Consulting Fees

Novel biomarkers in LBD - Implications for clinical trials

Lisa Vermunt, PhD MD *has nothing to disclose.*

2-18-PER-C The continued evolution of real-world data platforms to investigate Alzheimer's disease diagnosis, progression, treatment, and care.

RWD insights into disease progression

Maria Eriksdotter, MD, PhD, *prof has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai/Bioarctic Expert consultant Sept 19 2023 - Consulting Fees

Lundbeck - Ownership Interest

RWD insights into the use, safety and effectiveness of novel treatments

Atsushi Iwata, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Contracted Research

Daiichi Sankyo - Consulting Fees

Eisai - Consulting Fees

Eli Lilly - Consulting Fees

Fujifilm - Contracted Research

FujiRebio - Contracted Research

Roche - Contracted Research

SONY - Contracted Research

RWD insights into the global cost of Alzheimer's and dementia

Linus Jönsson, MD MSc PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

H. Lundbeck A/S - Consulting Fees

Janssen Pharmaceutica - Receipt of Intellectual Property Rights/Patent Holder

Novo Nordisk A/S - Contracted Research

Data harmonisation to foster collaboration between Alzheimer's disease registries

Robert Perneczky, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees

Eisai - Consulting Fees

Eli Lilly - Consulting Fees

Grifols - Consulting Fees

GSK - Consulting Fees

Novo Nordisk - Consulting Fees

Roche - Consulting Fees

Schwabe - Consulting Fees

Tabuk - Consulting Fees

Real-World Data on the diagnosis of Alzheimer's Disease in routine clinical practice: Insights from the Australian Dementia Network "ADNeT" Registry

Stephanie Alison Ward, BMed FRACP MPH *has nothing to disclose.*

Learning from Real-World Data Platforms: Insights into Care and Representation in Research Through ALZ-NET and New IDEAS

Charles Windon, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Kinetix Group -

1-13-PER-A Towards a cure: future treatments for AD

Brainshuttle technology: Focus on trontinemab and newly emerging therapies

Geoffrey A. Kerchner, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

F. Hoffmann-La Roche, Ltd. - Salary, Ownership Interest

Preventative treatments for AD and inflammation related targets

Jessica B. Langbaum, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Contracted Research

Targeting AD and its comorbidities with combination therapies

Teresa Leon *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Healios - Consulting Fees

Lexeo - Consulting Fees

Mynorix - Consulting Fees

Novo Nordisk - Ownership Interest

PharmaMar - Ownership Interest

Tau and other non-amyloid targets

Mark Mintun, MD *has nothing to disclose.*

3-PL Plenary Session

Bilingualism and dementia: Implications for brain health and policy development

Suvarna Alladi, DM *has nothing to disclose.*

Psychosis in Alzheimer's Disease

Clive G Ballard, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AARP - Consulting Fees

Acadia - Consulting Fees

Addex - Consulting Fees

Biogen - Consulting Fees

Bioexcel - Consulting Fees

Bristol Myer Squibb - Consulting Fees

Eli Lilly - Consulting Fees

exciva - Consulting Fees

GW pharma - Consulting Fees

Janssen - Consulting Fees

Johnson and Johnson - Consulting Fees

Novo Nordisk - Consulting Fees

Orion - Consulting Fees

Roche - Consulting Fees

Sunovion - Consulting Fees

Suven - Consulting Fees

TauRx - Consulting Fees

4-36-FRS-C Care access and costs across settings among PLWD

Blood biomarkers for Alzheimer's disease diagnosis in the context of disease-modifying treatment: a cost-utility analysis

Sandar Aye, MSc *has nothing to disclose.*

Accountable Care Organizations and Medicare Payments for Dementia Patients Across Race and Social Vulnerability

Jie Chen, PhD *has nothing to disclose.*

Direct and indirect costs of dementia in Brazil

Fabiana A F da Mata, PhD *has nothing to disclose.*

Projected differences in wait times for diagnosis of Alzheimer's disease for individuals dually eligible for Medicare and Medicaid in the U.S due to higher disease burden and obstacles to access

Soeren Mattke, MD, DSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AiCure Technologies -

Alzpath -

Boston Millenia Partners -

C2N - Consulting Fees

Eisai - Consulting Fees

Novo Nordisk - Consulting Fees

Roche - Consulting Fees

Senscio Systems -

Alzheimer's Disease Prediction and Implications for Insurance

Björn Schmitz-Luhn, J.D., Ph.D. (DE) *has nothing to disclose.*

The Evaluation of Telehealth Provider Payment Parity on Health Service Utilization among Adults with High Risk Factors for Dementia in the US

Zhang Zhang *has nothing to disclose.*

2-15-FRS-C Exploring new risk factors for dementia incidence and mortality

An atypical clinical phenotype is a risk factor for higher mortality in Alzheimer's disease

Ilse Bader, MSc. *has nothing to disclose.*

Neuroticism and risk of all-cause dementia, Alzheimer's disease, and vascular dementia: exploring modification by genetic risk and mediation by vascular and mental health

Yaqing Gao, MPH *has nothing to disclose.*

Current epidemiological and experimental evidence relating the chemical exposome to Alzheimer's disease

Sophie Lefèvre-Arbogast, PhD *has nothing to disclose.*

Association of Prenatal Pesticide Exposure with Plasma A β 42/40 Ratio in Midlife: Evidence from the Child Health and Development Studies

Jason R Richardson, Ph.D *has nothing to disclose.*

Externally Validated Dementia Risk Prediction Models: Can we make recommendations on which to implement in clinical and research settings?

Blossom CM Stephan, BA (Hons), PhD *has nothing to disclose.*

Lung function and risk of incident dementia: A prospective cohort study of 431,834 individuals

Liu Yang, MD *has nothing to disclose.*

4-27-FRS-C From prioritization to care provision: Current directions in disease-modifying treatments

Comparing the short-term and long-term impact of primary and secondary prevention strategies on population-level dementia burden: A microsimulation modelling study

Lynn Aasman *has nothing to disclose.*

Psychological effects of personalized dementia risk disclosure: The Barcelona β eta Dementia Prevention Research Clinic study

Oriol Grau-Rivera, MD, PhD *has nothing to disclose.*

Differences in Dementia Diagnosis Rates in Primary Care in Traditional Medicare and Medicare Advantage

Sidra Haye, PhD *has nothing to disclose.*

Dementia Research Priorities in Low- and Middle-income Countries in Southeast Asia: A scoping review of the literature and nominal group technique outcome.

Siti Maisarah Mattap, PhD *has nothing to disclose.*

Is the US infusion capacity sufficient for the expected demand with the emergence of disease-modifying Alzheimer's treatments?

Soeren Mattke, MD, DSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AiCure Technologies -

Alzpath -

Boston Millenia Partners -

C2N - Consulting Fees

Eisai - Consulting Fees

Novo Nordisk - Consulting Fees

Roche - Consulting Fees

Senscio Systems -

Assessing Alzheimer's Disease and Related Dementia risk in American Samoa using the Talanoa research framework.

Vaatausili Tofaeono, MBA *has nothing to disclose.*

2-33-FRS-C Global examinations on cognition and the critical roles of the social exposome and lifestyle factors

Investigation of Brain Signatures Across Diverse Metabolic States in MCI

Filippos Anagnostakis *has nothing to disclose.*

Dietary intervention, biomarkers of brain pathology and neurodegeneration, and cognition: The MIND Trial Study

Klodian Dhana, MD, PhD *has nothing to disclose.*

Multimodal Care Bundle Approach for Primary Prevention of Dementia in an Indian Cohort (SMRUTHI-India)

Aditi Dubey, MA, M.Phil *has nothing to disclose.*

Media Contribution to Dementia Awareness in Recruitment and Retention of Alzheimer's Disease Diversity Genetic Cohorts- Alzheimer's disease Sequencing Project in Africa

Temitope Hannah Farombi, MBBS, MSc *has nothing to disclose.*

"My Wife and I Invariably Go Together": A Mixed Methods Analysis of Physical Activity and its Influences on Older Adult Dyads

Jenny L Wales, MRes *has nothing to disclose.*

Integrating Coalitions, Strategic Planning, and Road Map Implementation in Alzheimer's Disease and Related Dementias Care: A Case Study from Mississippi

Kina L. White, DrPH, MHSA, FACHE *has nothing to disclose.*

2-27-FRS-C Living alone with dementia is common: international trends, challenges, and policies

Living alone with dementia in Japan: challenges and policies

Shuichi Awata, PhD, MD *has nothing to disclose.*

An intervention to support persons living alone with cognitive impairment in the United States

Allison Gibson, PhD, MSW *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Springer Publishing - Royalty

Care negotiation between people living alone with dementia in the United States and non-kin caregivers

Jane Lowers, PhD *has nothing to disclose.*

Long-term cost-effectiveness of collaborative dementia care for persons living alone versus those living with a caregiver in Germany

Bernhard Michalowsky, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consulting Fees

Lilly - Consulting Fees

Housing characteristics by living arrangement of older adults with cognitive impairment in the United States

Safiyyah Okoye, PhD, MSN *has nothing to disclose.*

Individuals with Alzheimer's disease living alone in Sweden receive limited comprehensive care

Dorota Religa, MD, PhD *has nothing to disclose.*

1-15-FRS-C Multidimensional approaches in cognitive preservation: Combining diet, exercise, and biomarker insights

MIND diet, Cerebrovascular Health, and Cognition among community-dwelling Older Adults

Puja Agarwal, PhD *has nothing to disclose.*

Exercise reduces white matter pathology in vascular cognitive impairment

Nárlon Cássio Boa Sorte Silva, PhD *has nothing to disclose.*

Cognitive and physical activity are related to increased cognitive reserve in a large memory clinic cohort

Diana I. Bocancea, MSc *has nothing to disclose.*

Adherence to the MIND Diet and Cognition in Older Adults: A Post-hoc Analysis of the MIND Trial

Klodian Dhana, MD, PhD *has nothing to disclose.*

PENSA study, results of a 12-month personalized intensive multimodal lifestyle intervention complemented with epigallocatechin gallate (EGCG) to prevent cognitive decline in *APOE-ε4* carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial

Laura Forcano, PhD *has nothing to disclose.*

Ten Year Patterns of Change in HbA1C and Risk of Dementia in a Diverse Cohort of Adults with Type 2 Diabetes

Rachel Whitmer, PhD *has nothing to disclose.*

4-15-PER-B New directions in exercise for prevention of Alzheimer's disease and dementia: a focus on blood-based biomarkers

Classic biomarkers in exercise research for brain health promotion: From cells to communities

Cindy K Barha, PhD *has nothing to disclose.*

Aerobic exercise and Alzheimer's disease blood-based biomarkers

Kirk I. Erickson, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

MedRhythms, Inc - Consulting Fees

Neo Auvra, Inc. - Consulting Fees

Resistance exercise and Alzheimer's disease blood-based biomarkers in European cognitively healthy older adults.

Irene Esteban-Cornejo, PhD *has nothing to disclose.*

Novel Alzheimer's disease blood-based biomarkers in exercise trials

Thomas K Karikari, PhD *has nothing to disclose.*

How does different types of exercise promote cognitive function? What do we know?

Teresa Liu-Ambrose, PhD, PT *has nothing to disclose.*

4-24-FRS-B The Impact of Adverse and Traumatic Social Conditions on the Risk for Alzheimer's Disease and Related Dementias Among Sexual and Gender Minority Communities

Adverse childhood experiences and subjective cognitive decline among transgender adults

Jobina Chiow, BSN Honors student *has nothing to disclose.*

Exploring the Cognitive Health of LGBTQIA+ Older Adults from The Stonewall Generations Study

Jason D. Flatt, PhD, MPH *has nothing to disclose.*

The role of social support and social contact in cognitive aging: A study of sex/gender and sexuality in the Health and Retirement Study

Douglas William Hanes, PhD *has nothing to disclose.*

Social Support, Isolation, and Cognitive Health among LGBTQ+ Older Adults in the United States

Nik M. Lampe, PhD *has nothing to disclose.*

Risk factors for subjective and objective cognitive decline in sexual minority older adults.

Riccardo Manca, PhD *has nothing to disclose.*

2-29-FRS-A Brain networks – Drivers or conduits of disease progression in Alzheimer’s disease?

Regional Amyloid Load Predicts Tau and Atrophy Dynamics

Pavan Chaggar, PhD *has nothing to disclose.*

Amyloid-associated hyperconnectivity drives tau spreading across connected brain regions in Alzheimer’s disease

Nicolai Franzmeier, PhD *has nothing to disclose.*

Synaptic loss pattern is associated with functional connectivity in Alzheimer’s disease

Ying Luan, PhD *has nothing to disclose.*

A primer on connectome-based models of neurodegenerative disease

Jacob W. Vogel, PhD *has nothing to disclose.*

3-17-FRS-C Metabolomics and glucose metabolism in Alzheimer's disease

Multi-cohort analyses link plasma GDF15 with dementia, brain atrophy, and plasma biomarkers

Cassandra O Blew *has nothing to disclose.*

The association of Diabetes Mellitus with Amyloid and Tau biomarkers

Stephan Duijkers, MSc *has nothing to disclose.*

Associations between glucose metabolism measures and amyloid and tau load on PET 14 years later: Findings from the Framingham Heart Study

Veerle van Gils, MSc *has nothing to disclose.*

Foodomics: Links to cognition and AD markers of disease.

Jennifer S Labus, PhD *has nothing to disclose.*

Brain metabolic alterations associated with cognitive resilience

Jun Li, MD, PhD *has nothing to disclose.*

Multi-tissue metabolomics analyses identify disrupted processes in Alzheimer's Disease

Ciyang Wang, BS *has nothing to disclose.*

4-2-FRS-D Tau accumulation and tau spreading patterns II

Support for transmission of tau pathology in humans using individualized epicenters and structural connectomes

Christopher Brown, MD, PhD *has nothing to disclose.*

Connectivity to epicenters of tau accumulation contributes to regional synaptic loss in Alzheimer's disease.

Michael Ewers, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Contracted Research

Combining multimodal connectivity information improves modelling of pathology spread in Alzheimer's disease

Elinor Thompson, PhD *has nothing to disclose.*

3-3-FRS-D Unravelling neurodegenerative pathways across Alzheimer's and related disorders I

Uncovering the role of white matter microstructure in longitudinal memory and executive function decline: insights from a multi-site study of 2,220 participants across 4,918 paired imaging-cognition sessions

Derek B. Archer, PhD *has nothing to disclose.*

Vulnerability of locus coeruleus projections during aging

Joana B Pereira, PhD *has nothing to disclose.*

Longitudinal neurodegeneration in relation to amyloid pathology among cognitively unimpaired individuals

Henry Gilreath Stephenson *has nothing to disclose.*

3-5-FRS-D Clinical trial case detection and outcomes I

Frontotemporal Degeneration (FTD): Community Perspectives on Clinical Trials

Shana G Dodge, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

UCB - Consulting Fees

Overview and Application of Intrasubject Variability in ADRD Research

Michael H. Malek-Ahmadi, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biomedical Research Alliance of New York - Consulting Fees

Precision Phenotyping of Mild Behavioral Impairment and the Early Detection of Dementia

Ipsit V Vahia, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Mary Ann Morse Senior Living - Salary

Otsuka - Consulting Fees

4-5-FRS-D Clinical trial case detection and outcomes II

Automated Physical Performance Battery as a Digital Marker for Alzheimer's Disease and Mild Cognitive Impairment

Ehsan Adeli, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

SolveMed Group - Salary

Stanford University - Salary

Exploring the differential impact of sociodemographic and extrinsic factors on mobility-based digital phenotypes versus standard cognitive tests among older adults

Katherine Hackett, PhD *has nothing to disclose.*

Using Motor Learning to Predict Cognitive and Functional Decline in Mild Cognitive Impairment and Alzheimer's Disease

Vincent Koppelmans, PhD *has nothing to disclose.*

3-34-FRS-C Neurobiology of behaviour across the cognitive continuum

Atrophy Network Mapping of Anxiety in Cognitively Unimpaired Older Adults in Preclinical AD

Soyoung Lee, MD *has nothing to disclose.*

Association between Cortical Thickness and Mild Behavioral Impairment in a Southeast Asian Population - Biomarkers and Cognition Study, Singapore BIOCIS

Yi Jin Leow, Grad.Dip(ClinPsych) *has nothing to disclose.*

Association of CSF AD biomarkers and lifestyle factors with neuropsychiatric symptoms among non-demented older persons

Anja Soldan, PhD *has nothing to disclose.*

Neuropsychiatric symptoms and brain aging in mild cognitive impairment and early dementia: A multicenter study

Daichi Sone, MD, PhD *has nothing to disclose.*

A multi-dimensional context-dependent measurement framework for affective experience in preclinical AD

Adam Turnbull, PhD *has nothing to disclose.*

Driving Behavior as a Functional Biomarker of Preclinical Alzheimer Disease

Julie K. Wisch, PhD *has nothing to disclose.*

4-PL Plenary

Dementia research in low- and middle-income countries (LMICs): Initiatives that seize opportunities, overcome challenges, and build capacity

Ricardo Allegri, MD, PhD *has nothing to disclose.*

Synaptic oligomeric tau in Alzheimer's disease—A potential culprit in the spread of tau pathology through the brain

Tara L Spires-Jones, DPhil *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Scottish Brain Sciences - Consulting Fees

3-14-FRS-C Drug discovery and delivery for Alzheimer's disease and related dementias

The inverse association between cancer and Alzheimer's disease: evidence from neuropathological studies

Erin L Abner, PhD, MPH *has nothing to disclose.*

what do reactive astrocytes (really) do?

Shane A. Liddelow, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
AstronauTx - Ownership Interest
Synapticure - Ownership Interest

Characterization of the first TREM2 small molecule agonist, VG-3927, for clinical development in Alzheimer's disease

Christian Mirescu, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Vigil Neuroscience, Inc - Ownership Interest

Targeted degradation of a-synuclein via the AdPROM system prevents PFF-induced a-synuclein aggregation

Diederik Moechars, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Johnson & Johnson Innovative Medicine - Salary

Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood-Brain Barrier Opening and Delivery of a Novel Anti-Amyloid Re Complex for Memory Improvement in a 3xTg-Alzheimer's Disease Mouse Model

Rebecca L Noel, MS *has nothing to disclose.*

Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies

Marija Vukicevic, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune SA - Salary

